HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Jan. 19, 2018 (HealthDay News) -- A multi-analyte blood test, CancerSEEK, can detect eight common cancer types, with high sensitivity and specificity, according to a study published online Jan. 18 in Science.
Joshua D. Cohen, from Johns Hopkins University School of Medicine in Baltimore, and colleagues describe a blood test that can detect eight common cancer types through assessment of circulating protein levels and mutations in cell-free DNA. The test was applied to 1,005 patients with non-metastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast.
The researchers found that in a median of 70 percent of the eight cancer types, CancerSEEK tests were positive. For detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals, the sensitivities ranged from 69 to 98 percent. The specificity of the test was above 99 percent; positive scores occurred in only seven of 812 healthy controls. In a median of 83 percent of the patients, CancerSEEK also localized the cancer to a small number of anatomic sites.
"Our study lays the conceptual and practical foundation for a single, multi-analyte blood test for cancers of many types," the authors write. "To actually establish the clinical utility of CancerSEEK and to demonstrate that it can save lives, prospective studies of all incident cancer types in a large population will be required."
Several authors disclosed financial ties to pharmaceutical and diagnostics companies, and some are inventors on a patent application that involves the multi-analyte approach involved in the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 28, 2022